Abstract
Background: Dementia is a complex pathological state that affects millions of individuals worldwide and is responsible for a huge socioeconomic burden, making it a major health concern of current times. Given the impact of dementia in both patients and caregivers, it is crucial to fully clarify the molecular mechanisms underlying dementia-associated disorders, since without this knowledge our ability to correctly diagnose and treat these diseases is severely hampered.
Methods: Epigenetic mechanisms, such as miRNA-mediated post-transcriptional regulation, have been reported to play a role in dementia pathogenesis. Given their ability to bind complementary mRNA sequences, miRNAs are able to induce temporary or permanent translation repression of their mRNA targets.
Results: Consequently, changes in miRNA levels may contribute to alterations in the expression of dementiarelated proteins, impacting the course of the disease. Conversely, studies have also reported that some of these proteins are able to regulate the biogenesis and transport of miRNAs, hinting at novel disease-related mechanisms that are now beginning to be explored. These findings have made miRNAs both interesting tools and promising targets in the design of novel therapeutic strategies. Moreover, the discovery of circulating miRNAs, which are released by cells of various tissues, including the brain, and travel in membrane-bound vesicles found in most biofluids, opened new possibilities concerning the usefulness of miRNAs as biomarkers of disease.
Conclusion: In this context, the major aim of this review is to discuss the relevance of these small non-coding RNAs in dementia, focusing on their role as gene expression regulators, their potential as biomarkers of dementia subtype and stage, and the hypothesis of using miRNA modulation as an innovative therapeutic approach to treat dementia-related disorders.
Keywords: Dementia, microRNAs, biomarkers, therapy, immune system, neurodegeneration, neuroinflammation.
Current Pharmaceutical Design
Title:miRNAs: New Biomarkers and Therapeutic Targets in Dementia
Volume: 23 Issue: 5
Author(s): Ana Teresa de Barros Viegas, Joana Ribeiro Guedes, Ana Rafaela Oliveira, Ana Maria Sequeira Cardoso and Ana Luisa Colaco Cardoso
Affiliation:
Keywords: Dementia, microRNAs, biomarkers, therapy, immune system, neurodegeneration, neuroinflammation.
Abstract: Background: Dementia is a complex pathological state that affects millions of individuals worldwide and is responsible for a huge socioeconomic burden, making it a major health concern of current times. Given the impact of dementia in both patients and caregivers, it is crucial to fully clarify the molecular mechanisms underlying dementia-associated disorders, since without this knowledge our ability to correctly diagnose and treat these diseases is severely hampered.
Methods: Epigenetic mechanisms, such as miRNA-mediated post-transcriptional regulation, have been reported to play a role in dementia pathogenesis. Given their ability to bind complementary mRNA sequences, miRNAs are able to induce temporary or permanent translation repression of their mRNA targets.
Results: Consequently, changes in miRNA levels may contribute to alterations in the expression of dementiarelated proteins, impacting the course of the disease. Conversely, studies have also reported that some of these proteins are able to regulate the biogenesis and transport of miRNAs, hinting at novel disease-related mechanisms that are now beginning to be explored. These findings have made miRNAs both interesting tools and promising targets in the design of novel therapeutic strategies. Moreover, the discovery of circulating miRNAs, which are released by cells of various tissues, including the brain, and travel in membrane-bound vesicles found in most biofluids, opened new possibilities concerning the usefulness of miRNAs as biomarkers of disease.
Conclusion: In this context, the major aim of this review is to discuss the relevance of these small non-coding RNAs in dementia, focusing on their role as gene expression regulators, their potential as biomarkers of dementia subtype and stage, and the hypothesis of using miRNA modulation as an innovative therapeutic approach to treat dementia-related disorders.
Export Options
About this article
Cite this article as:
Viegas Teresa de Barros Ana, Guedes Ribeiro Joana, Oliveira Rafaela Ana, Cardoso Maria Sequeira Ana and Cardoso Luisa Colaco Ana, miRNAs: New Biomarkers and Therapeutic Targets in Dementia, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612823666170111094702
DOI https://dx.doi.org/10.2174/1381612823666170111094702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological
Review
The Natural Products Journal Olanzapine Does not Aggrevate Ischemic Neuronal Injury by Focal Cerebral Ischemia: A Dose Related Restriction of the Neuroprotective Effect?
Medicinal Chemistry Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry Oxysterol Derivatives of Cholesterol in Neurodegenerative Disorders
Current Medicinal Chemistry Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds The MMP-2/TIMP-2 System in Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Enantioselective, Potentiometric Membrane Electrodes (EPME) Based on Maltodextrins for the Determination of L-Vesamicol in Serum Samples
Current Pharmaceutical Analysis Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry